UREA CYCLE DISORDER TREATMENT MARKET ANALYSIS

Urea Cycle Disorder Treatment Market, by Treatment Type (Amino Acid Supplements, Sodium Phenylbutyrate, Glycerol Phenylbutyrate, Sodium Benzoate, and Others (Low Protein Diet, Carglumic acid, etc.), By Enzyme Deficiency Type (OTC – Ornithine Transcarbamylase, AS – Argininosuccinate Synthetase (citrullinemia), AG – Arginase, AL – Argininosuccinate Lyase, CPS1 – Carbamoyl Phosphate Synthase, and NAGS – N-acetylglutamate Synthase), By Route of Administration (Oral and Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Published In : May 2021
Code : CMI4441
Pages :272
Formats :
Excel and PDF
Industry : Pharmaceutical

Urea Cycle Disorder Treatment MarketSize and Trends

The global urea cycle disorders treatment market is estimated to be valued at US$ 1,188.9 million in 2020 and is expected to exhibit a CAGR of 3.5 % during the forecast period (2020-2027).

The increasing prevalence of urea cycle disorder is expected to drive growth of the global urea cycle disorders treatment market over the forecast period. For instance, according to the article published in the Orphanet Journal of Rare Diseases in June 2017, in 2017 the estimated prevalence of ornithine transcarbamylase deficiency ranges between 1/56,500 to 1/113,000 live births across the world.

Moreover, the increasing initiatives by key players operating in the market for supporting patients suffering from UCD is expected to fuel growth of the global urea cycle disorders treatment market in the near future.

For instance, in March 2017, Horizon Pharma plc. launched UCD in Common, an initiative for people suffering from urea cycle disorder, in order to offer supportive, educational, and interactive resources to the patients living with UCD, their families, caregivers, and healthcare professionals.

Market Trends